A Phase 3 interventional study of avacincaptad pegol in Geographic Atrophy and Age-Related Macular Degeneration, sponsored by Astellas Pharma Global Development, Inc.. Completed at 117 sites in 17 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-05-18.
Sponsored by Astellas Pharma Global Development, Inc. (part of Astellas Pharma Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 131 studies in Geographic Atrophy with a site in United States — 35 open to participants now, 45 under way, 5 of them phase 3. Geographic Atrophy · United States.
Among the 131 studies in Geographic Atrophy with a site in United States, this one is the 29th largest by enrollment of the 107 interventional ones that give a count, is one of 5 that started in 2022, is one of 15 in phase 3, and was the 84th registered.
188 studies on the registry are indexed under Geographic Atrophy; 52 are open to participants now.
Browse Geographic Atrophy studies →35 of the 131 studies in Geographic Atrophy with a site in United States are open now. Recruiting first, the newest first:
Genentech, Inc. · Sites in United States
Ages 50+
Biojiva LLC · Sites in United States, Australia
Ages 55+
Sitala Bio LTD · Sites in United States, Argentina, Australia and 4 more countries
Ages 60+
University of Utah · Sites in United States
Ages 65–90
Cellio Therapeutics Inc · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 40 Geographic Atrophy studies recruiting now, 31 (78%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
131 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 33 · Phase 2 65 · Phase 3 20
First in 2000; this study’s year is marked. 5 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 278 is above the median of 70 across 141 interventional studies indexed under Geographic Atrophy.
Median enrollment 98 across the 107 interventional studies, 138 across the 24 observational. Of the 79 that completed or were terminated, 40 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
109 of 131 have an industry lead sponsor. The 10 most frequent:
This study is registered under Astellas Pharma Global Development, Inc., one of the names counted as Astellas Pharma Inc. Under that name alone:
Astellas Pharma Global Development, Inc. is the lead sponsor of 207 studies on the registry; 23 are open to participants now.
Of its 82 completed or terminated interventional studies of FDA-regulated products, 38 (46%) have results posted.
Astellas Pharma Inc has 8 studies filed under Geographic Atrophy — fewer than ten, so there is no comparison to draw.
12 of the studies in Geographic Atrophy with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05949593Phase 3Belite Bio, IncPhase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy | 2027-06-30 |
| NCT06510816Phase 3Annexon, Inc.A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA) | 2027-07-31 |
| NCT06769048Boehringer IngelheimA Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy | 2026-12-22 |
| NCT07747662University of Wisconsin, MadisonAdaptive Optics Scanning Light Ophthalmoscopy (AOSLO) and Microperimetry (MP) Sub-study | 2027-02 |
| NCT07144137Complement TherapeuticsA Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA) | 2027-03-31 |
Add all 12 to your calendar (.ics) → With an account.
Among the 131 studies in Geographic Atrophy with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess long-term safety of avacincaptad pegol intravitreal administration for patients with geographic atrophy (GA) who completed Study ISEE2008 (GATHER2) through the Month 23 visit on study treatment (either avacincaptad pegol or Sham).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive avacincaptad pegol 2 mg monthly from Month 1 to Month 17.
Drug: avacincaptad pegol
Intravitreal Injection
Also known as: Zimura (previous name), ARC1905, Izervay
Number of Participants With Adverse Events (AEs)
An AE is defined as any untoward medical occurrence in a participant including unfavorable and unintended signs, symptoms or disease temporally associated with the use of a medicinal product and which does not necessarily have to have a causal relationship to this treatment. AEs include illnesses with onset during the trial, or exacerbations of pre-existing illnesses. Exacerbation of pre-existing illness is defined as a significant increase in the severity of the illness as compared to the start of the trial and was considered when a participant requires new or additional treatment for that illness. Lack of or insufficient clinical response or efficacy was not recorded as an AE.
Time frame: Up to 18 months
Number of Participants With Anti-drug Antibody (ADA)
Number of participants with ADA = Post-baseline positive (in Baseline negative group) + treatment-boosted ADA positive (in Baseline positive group) / participants with a Baseline and at least one post-baseline sample. For participants whose ADA status is positive at Baseline, a post-baseline titer value that is \>= 4 times higher than the Baseline is considered treatment-boosted ADA.
Time frame: Up to 18 months
Plasma Concentrations of ACP
Concentrations below the lower limit of quantification (3.36 ng/mL) are set to zero for calculation of summary statistics.
Time frame: Months 1, 2, 4, 7, 13, and 18
Participants who completed study ISEE2008 (NCT04435366; GATHER2) through the Month 23 visit on assigned treatment (avacincaptad pegol \[ACP\] or sham) were enrolled in the study.
| Milestone | ACP Every Month (EM) to ACP EM | ACP EM/Every Other Month (EOM) to ACP EM | Sham to ACP EM |
|---|---|---|---|
| Started | 64 | 62 | 152 |
| Completed | 56 | 54 | 127 |
| Not completed | 8 | 8 | 25 |
| Withdrew: Adverse event | 1 | 3 | 7 |
| Withdrew: Other | 1 | 0 | 2 |
| Withdrew: Death | 0 | 1 | 1 |
| Withdrew: Participant request | 5 | 2 | 10 |
| Withdrew: Sponsor decision | 1 | 0 | 2 |
| Withdrew: Investigator decision | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 2 | 2 |
An AE is defined as any untoward medical occurrence in a participant including unfavorable and unintended signs, symptoms or disease temporally associated with the use of a medicinal product and which does not necessarily have to have a causal relationship to this treatment. AEs include illnesses with onset during the trial, or exacerbations of pre-existing illnesses. Exacerbation of pre-existing illness is defined as a significant increase in the severity of the illness as compared to the start of the trial and was considered when a participant requires new or additional treatment for that illness. Lack of or insufficient clinical response or efficacy was not recorded as an AE.
| Participants | ACP EM to ACP EM | ACP EM/EOM to ACP EM | Sham to ACP EM |
|---|---|---|---|
| Number of Participants With Adverse Events (AEs) | 50 | 49 | 129 |
Number of participants with ADA = Post-baseline positive (in Baseline negative group) + treatment-boosted ADA positive (in Baseline positive group) / participants with a Baseline and at least one post-baseline sample. For participants whose ADA status is positive at Baseline, a post-baseline titer value that is \>= 4 times higher than the Baseline is considered treatment-boosted ADA.
| Participants | ACP EM to ACP EM | ACP EM/EOM to ACP EM | Sham to ACP EM |
|---|---|---|---|
| Number of Participants With Anti-drug Antibody (ADA) | 1 | 0 | 2 |
Concentrations below the lower limit of quantification (3.36 ng/mL) are set to zero for calculation of summary statistics.
| ng/mL | ACP EM to ACP EM | ACP EM/EOM to ACP EM | Sham to ACP EM |
|---|---|---|---|
| Month 1 | 9.17 ± 20.9 | 5.97 ± 13.9 | 0.0440 ± 0.537 |
| Month 2 | 35.6 ± 21.8 | 31.7 ± 24.4 | 31.9 ± 19.3 |
| Month 4 | 41.1 ± 28.3 | 37.8 ± 38.3 | 34.6 ± 23.3 |
| Month 7 | 33.7 ± 27.3 | 30.0 ± 23.1 | 37.5 ± 30.8 |
| Month 13 | 44.8 ± 29.8 | 34.4 ± 29.4 | 36.0 ± 29.3 |
| Month 18 | 42.3 ± 33.7 | 38.7 ± 30.2 | 33.9 ± 30.1 |
Collected over All-cause mortality: From randomization up to 18 months. AEs: From first dose of study drug up to 18 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ACP EM to ACP EM | 0/64 (0%) | 14/64 (21.9%) | 42/64 (65.6%) |
| ACPEM/EOM to ACP EM | 2/62 (3.2%) | 13/61 (21.3%) | 39/61 (63.9%) |
| Sham to ACP EM | 3/152 (2%) | 24/151 (15.9%) | 93/151 (61.6%) |
| Event | ACP EM to ACP EM | ACPEM/EOM to ACP EM | Sham to ACP EM |
|---|---|---|---|
| Acute myocardial infarctionCardiac disorders | 0/64 | 1/61 | 0/151 |
| Atrial fibrillationCardiac disorders | 0/64 | 1/61 | 0/151 |
| Cardiac failureCardiac disorders | 0/64 | 1/61 | 0/151 |
| Cardio-respiratory arrestCardiac disorders | 0/64 | 1/61 | 0/151 |
| CataractEye disorders | 0/64 | 1/61 | 0/151 |
| ColitisGastrointestinal disorders | 0/64 | 1/61 | 0/151 |
| Large intestine polypGastrointestinal disorders | 0/64 | 1/61 | 0/151 |
| Device related infectionInfections and infestations | 0/64 | 1/61 | 0/151 |
| PneumoniaInfections and infestations | 1/64 | 1/61 | 1/151 |
| Femoral neck fractureInjury, poisoning and procedural complications | 0/64 | 1/61 | 0/151 |
| Event | ACP EM to ACP EM | ACPEM/EOM to ACP EM | Sham to ACP EM |
|---|---|---|---|
| CataractEye disorders | 6/64 | 10/61 | 14/151 |
| Intraocular pressure increasedInvestigations | 9/64 | 10/61 | 21/151 |
| Choroidal neovascularisationEye disorders | 10/64 | 3/61 | 20/151 |
| FallInjury, poisoning and procedural complications | 9/64 | 4/61 | 12/151 |
| COVID-19Infections and infestations | 8/64 | 5/61 | 9/151 |
| Visual acuity reducedEye disorders | 4/64 | 3/61 | 18/151 |
| Conjunctival haemorrhageEye disorders | 7/64 | 6/61 | 17/151 |
| Urinary tract infectionInfections and infestations | 5/64 | 2/61 | 11/151 |
| Vitreous detachmentEye disorders | 4/64 | 4/61 | 3/151 |
| BronchitisInfections and infestations | 2/64 | 4/61 | 3/151 |
Full Analysis Set (FAS) included all enrolled participants.
| Age, Continuous(years) | ACP EM to ACP EM | ACP EM/EOM to ACP EM | Sham to ACP EM | Total |
|---|---|---|---|---|
| Mean | 75.9 ± 9.3 | 78.6 ± 8.1 | 77.9 ± 8.4 | 77.6 ± 8.6 |
| Age, Customized(Participants) | ACP EM to ACP EM | ACP EM/EOM to ACP EM | Sham to ACP EM | Total |
|---|---|---|---|---|
| In Utero | 0 | 0 | 0 | 0 |
| Pre-term newborn - gestational age < 37 wk | 0 | 0 | 0 | 0 |
| Newborns (0-27 days) | 0 | 0 | 0 | 0 |
| Infants and toddlers (28 days-23 months) | 0 | 0 | 0 | 0 |
| Children (2-11 years) | 0 | 0 | 0 | 0 |
| Adolescents (12-17 years) | 0 | 0 | 0 | 0 |
| Adults (18-64 years) | 9 | 3 | 11 | 23 |
| Elderly (From 65-84 years) | 44 | 41 | 108 | 193 |
| Elderly 85 years and over | 11 | 18 | 33 | 62 |
| Sex: Female, Male(Participants) | ACP EM to ACP EM | ACP EM/EOM to ACP EM | Sham to ACP EM | Total |
|---|---|---|---|---|
| Female | 46 | 38 | 105 | 189 |
| Male | 18 | 24 | 47 | 89 |
| Ethnicity (NIH/OMB)(Participants) | ACP EM to ACP EM | ACP EM/EOM to ACP EM | Sham to ACP EM | Total |
|---|---|---|---|---|
| Hispanic or Latino | 5 | 4 | 7 | 16 |
| Not Hispanic or Latino | 52 | 45 | 126 | 223 |
| Unknown or Not Reported | 7 | 13 | 19 | 39 |
| Race/Ethnicity, Customized(Participants) | ACP EM to ACP EM | ACP EM/EOM to ACP EM | Sham to ACP EM | Total |
|---|---|---|---|---|
| White | 57 | 47 | 130 | 234 |
| Black or African American | 0 | 0 | 1 | 1 |
| Asian | 0 | 0 | 1 | 1 |
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Other | 0 | 2 | 1 | 3 |
| Not Reported | 7 | 13 | 19 | 39 |
| Unknown | 0 | 0 | 0 | 0 |
Showing the first 100 of 117 sites across 17 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.
Access criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.
Data sharing details ↗ · www.clinicaltrials.astellas.com
Ran from Sep 2022 to primary completion in Apr 2025, 30 months.
Results were first posted in Apr 2026, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Avacincaptad pegol
Astellas Pharma Global Development, Inc. →